{"schema_version":"secwatch.filing_event.v1","accession":"0001062993-26-004806","form_type":"8-K","ticker":"MDCX","cik":"0001997296","company_name":"Medicus Pharma Ltd.","filed_at":"2026-09-03T12:00:27+00:00","discovered_at":"2026-09-03T12:05:00.421334+00:00","generated_at":"2026-09-03T12:05:19.478078+00:00","sec_items":["1.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Medicus signs co-development license with Pfizer for CD228V ADC; $1B milestones","bullets":["Exclusive worldwide license from Pfizer to develop/commercialize CD228V, an early-stage antibody-drug conjugate targeting CD228.","Medicus pays $12.0M upfront plus $15.0M on first anniversary; Pfizer pays $2.0M development funding payment.","Pfizer eligible for development, regulatory, and sales milestones exceeding $1.0B total, plus low double-digit tiered royalties.","Medicus retains sole control over development, manufacture, regulatory approval, and commercialization; Pfizer holds option to fund pivotal trials.","Deal effective September 2, 2026; filed as Exhibit 10.1 with redactions for confidential terms."],"urls":{"canonical":"https://secwatch.observer/filing/0001062993-26-004806","json":"https://secwatch.observer/filing/0001062993-26-004806.json","markdown":"https://secwatch.observer/filing/0001062993-26-004806.md","text":"https://secwatch.observer/filing/0001062993-26-004806.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1997296/000106299326004806/0001062993-26-004806-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1997296/000106299326004806/form8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-09-03T12:05:19.478078+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}